MediaMedic

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

By Peter W. PENG 2025.12.18

At the 67th Annual Meeting of the American Society of Hematology (ASH), Professor Lu Peihua and Professor Zhang Xian from Lu Daopei Hospital presented a large-scale clinical study of a…

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

By Mourabit Halima 2025.12.17

Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

By Mourabit Halima 2025.12.17

On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

By Peng Longmei 2025.12.17

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

By Mourabit Halima 2025.12.17

At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

By Peter W. PENG 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

By Peng Longmei 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

By Mourabit Halima 2025.12.16

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

By Mourabit Halima 2025.12.15

To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, and accelerate translation through global collaboration, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held on…

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

By Mourabit Halima 2025.12.15

At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…

The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology

The 14th Lu Daopei Hematology Forum | Dongchu Wang: Unlocking the Predictive Value of Cytokines and Optimizing the Entire Treatment Pathway—Research and Prospects of CD7 CAR-T as a Bridge to Transplantation

The 14th Lu Daopei Hematology Forum | Dr. Shu Yan: Stratified Prevention and Control, Comprehensive Management—Strategies for the Diagnosis and Treatment of Invasive Fungal Disease After Hematopoietic Stem Cell Transplantation

The 14th Lu Daopei Hematology Forum | Dr. Jiujiang He: Establishing Venetoclax as a Cornerstone and Exploring Standardized Practice—Clinical Applications and Future Perspectives of Venetoclax in AML

the 14th Lu Daopei Hematology Forum丨Dr. Xiaosu Zhou: Decoding the “Genetic Code” of Atypical APL — Far Greater Complexity and Heterogeneity Than Expected

Frontiers in Immunology | Germline Genetic Susceptibility Genes May Enable More Precise Donor Selection for Hematopoietic Stem Cell Transplantation — Clinical Insights from a 558-Patient Transplant Cohort

Nature Reviews | The International Chinese Young Scholars Alliance for the Study of the Liver Facilitates Global Collaboration

ESMO 2026丨Looking Ahead: A Quick Review of 26 Chinese Hematologic Oncology Studies Featured at ESMO

The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology

The 14th Lu Daopei Hematology Forum | Dongchu Wang: Unlocking the Predictive Value of Cytokines and Optimizing the Entire Treatment Pathway—Research and Prospects of CD7 CAR-T as a Bridge to Transplantation

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.